Paul Tudor Jones Amylyx Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $56,636 - $408,993	-20,899 Reduced 62.1%	12,753 $36,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $75,956 - $116,168	6,293 Added 23.0%	33,652 $495,000
Q3 2023 Nov 15, 2023	SELL	$18.08 - $23.45 $583,188 - $756,403	-32,256 Reduced 54.11%	27,359 $500,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $462,629 - $692,842	22,051 Added 58.7%	59,615 $1.29 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $43,421 - $64,137	1,567 Added 4.35%	37,564 $1.1 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $590,805 - $779,664	19,859 Added 123.06%	35,997 $1.33 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $276,766 - $498,986	16,138 New	16,138 $454,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.